Alones Creative/iStock via Getty Images Quantum Computing’s Meteoric Rise Quantum Computing ( NASDAQ: QUBT ) stock skyrocketed nearly 53% on Wednesday. The rally followed news earlier in the week that the photonics company won a contract with NASA to utilize Dirac-3, its entropy quantum optimization machine, to support I am Steven Cress, Head of Quantitative Strategies at Seeking Alpha. I manage the quant ratings and factor grades on stocks and ETFs in Seeking Alpha Premium. I also lead Alpha Picks , which selects the two most attractive stocks to buy each month, and also determines when to sell them. Steven Cress is VP of Quantitative Strategy and Market Data at Seeking Alpha. Steve is also the creator of the platform’s quantitative stock rating system and many of the analytical tools on Seeking Alpha. His contributions form the cornerstone of the Seeking Alpha Quant Rating system, designed to interpret data for investors and offer insights on investment directions, thereby saving valuable time for users. He is also the Founder and Co-Manager of Alpha Picks, a systematic stock recommendation tool designed to help long-term investors create a best-in-class portfolio. Steve is passionate and dedicated to removing emotional biases from investment decisions. Utilizing a data-driven approach, he leverages sophisticated algorithms and technologies to simplify complex, laborious investment research, creating an easy-to-follow, daily updated grading system for stock trading recommendations. Steve was previously the Founder and CEO of CressCap Investment Research until its acquisition by Seeking Alpha in 2018 for its unparalleled quant analysis and market data capabilities. Prior to that, he had also founded the quant hedge fund Cress Capital Management, after spending most of his career running a proprietary trading desk at Morgan Stanley and leading international business development at Northern Trust. With over 30 years of experience in equity research, quantitative strategies, and portfolio management, Steve is well-positioned to speak on a wide range of investment topics. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given that any particular security, portfolio, transaction or investment strategy is suitable for any specific person. The author is not advising you personally concerning the nature, potential, value or suitability of any particular security or other matter. You alone are solely responsible for determining whether any investment, security or strategy, or any product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. Steven Cress is the Head of Quantitative Strategy at Seeking Alpha. Any views or opinions expressed herein may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.PHILADELPHIA--(BUSINESS WIRE)--Dec 19, 2024-- Aramark (NYSE: ARMK), a global leader in food and facilities management, announced today that Avendra International acquired the Quantum Cost Consultancy Group. The acquisition further enhances the company’s position as a leading global professional procurement and supply chain services provider, to a wide range of clients including hotels, hospitality and leisure resorts, healthcare, and educational institutions worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241219109142/en/ Quantum has customer spend of nearly half a billion dollars (converted to US currency) and has operations in Spain, Portugal, Germany, the Netherlands, Zanzibar, Mexico, the Dominican Republic, and Jamaica. “We are very pleased to bring Quantum into our portfolio,” said Autumn Bayles, Aramark’s Senior Vice President of Global Supply Chain and Group Purchasing Organizations. “Both companies share a similar vision and culture and adding Quantum positions us to better globally serve not only the hotel category, but several other hospitality markets in the Quantum geographies.” Quantum’s associates and clients can expect a seamless transition to Avendra International over the coming weeks. Their CEO will continue to lead the Quantum business and operations will remain unchanged. “We are excited to begin our next chapter as part of Avendra International,” said Alex Casajuana, Chief Executive Officer of Quantum. “Our associates, clients and suppliers will not see any changes in how the company operates and we are now better positioned to provide stronger outcomes for our clients and suppliers.” Quantum manages, to varying degrees, the expense categories that a hotel establishment might incur, including food and beverage, housekeeping and non-consumable products, services, energy and telecommunications, maintenance expenditures, small equipment, and insurances. “Our purchase of Quantum is part of our strategy to expand the footprint of Avendra International and strengthen our purchasing capacity in hospitality related products, services and engineering solutions in particular,” said Ian Murphy, Aramark’s European Senior Vice President of Supply Chain and Group Purchasing Organizations. In addition to hotels, Quantum also serves restaurants, gaming establishments, and senior and youth residencies. This purchase represents part of Aramark’s “tuck in” acquisition strategy to position the company for continued profitable growth. About Avendra International Avendra International is a leading strategic procurement and supply chain partner to a wide range of organizations, including hotels, hospitality and leisure resorts, healthcare, and educational institutions worldwide. Avendra International leverages $20.5 billion in procurement power and combines supply chain resources backed by Aramark’s global footprint across 15 countries. What makes us stand out is our team of local experts who are deeply knowledgeable about the cultural, industry and sector-specific nuances of each country we operate in. Whether clients aim to reduce costs, boost efficiency, drive innovation, or achieve sustainability targets, we provide the support they need to succeed. By harnessing our tailored solutions, advanced technology, and industry expertise, we enable organisations to thrive. About Aramark Aramark (NYSE: ARMK) proudly serves the world’s leading educational institutions, Fortune 500 companies, world champion sports teams, prominent healthcare providers, iconic destinations and cultural attractions, and numerous municipalities in 15 countries around the world with food and facilities management. Because of our hospitality culture, our employees strive to do great things for each other, our partners, our communities, and the planet. Aramark has been recognized on FORTUNE’s list of “World’s Most Admired Companies,” The Civic 50 by Points of Light 2024, Fair360’s “Top 50 Companies for Diversity” and “Top Companies for Black Executives,” Newsweek’s list of “America’s Most Responsible Companies 2024,” the HRC’s “Best Places to Work for LGBTQ Equality,” and earned a score of 100 on the Disability Equality Index. Learn more at www.aramark.com and connect with us on LinkedIn , Facebook , X , and Instagram . View source version on businesswire.com : https://www.businesswire.com/news/home/20241219109142/en/ Chris Collom, 215-238-3593,collom-chris@aramark.com KEYWORD: PENNSYLVANIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SUPPLY CHAIN MANAGEMENT RETAIL RESTAURANT/BAR LODGING DESTINATIONS TRAVEL FOOD/BEVERAGE SOURCE: Aramark Copyright Business Wire 2024. PUB: 12/19/2024 01:40 PM/DISC: 12/19/2024 01:38 PM http://www.businesswire.com/news/home/20241219109142/en11 vipph login register 。

HOUSTON — Start 2025 by leaving heart health worries behind! Advances in medical technology mean treating conditions like heart valve disease is now less invasive than ever. Many procedures no longer require major surgeries, but early detection and the right doctor are key. Dr. Devang Parikh and the team at Modern Heart and Vascular Institute provide cutting-edge care for patients of all ages, with convenient locations across Greater Houston. Book your appointment today at modernheartandvascular.com or call 832-644-8930. Make 2025 your healthiest year yet! This content sponsored by Modern Heart and VascularImpact Of The Growing Entertainment Industry: A Key Driver Transforming The Professional Audio Visual (AV) Market 2024

BERWYN, Pa.--(BUSINESS WIRE)--Nov 21, 2024-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) , a company specializing in developing pharmaceutical products for pain management, announced that it has been granted an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the National Institutes of Health (NIH), U.S. Department of Health and Human Services. This collaboration is for the continued development of Virpax’s product candidate, NES100, an intranasal peptide, for the management of acute and chronic non-cancer pain. NES100 is an enkephalin drug product based on a type of nanotechnology delivery approach. Enkephalin is a naturally occurring (endogenous) peptide that is not easily administered in its original form. We believe that the nanotechnology may enable and enhance the delivery of this metabolically labile peptide drug into the brain. NES100 is the first investigational product formulation delivered via the nasal route with the potential to enhance enkephalin transport to the brain. NES100 uses a preassembled device and cartridge to propel the enkephalin formulation through the nose to the brain by flowing along the olfactory nerve pathway. The Molecular Envelope Technology (MET) is designed to protect and help carry the drug to the brain with the goal of promptly suppressing pain by binding to the delta opioid receptors. NES100 has demonstrated analgesic potential in animal models without the development of opioid tolerance, withdrawal, respiratory depression, euphoria, or addiction associated with use of opioids. Jatinder Dhaliwal, Chief Executive Officer of Virpax, commented, "We are excited that this collaboration has been extended with NCATS and the NIH Helping to End Addiction Long-term (HEAL) initiative as we believe that it may help Virpax develop an effective and safe alternative to conventional opioids used by patients to manage acute and chronic pain. We believe that the NIH/NCATS collaborative agreement will enable our team to maintain momentum in both our pre-clinical and clinical development strategies." About Virpax Pharmaceuticals Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. ProbudurTM is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and EnveltaTM is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop one other prescription product candidate, NobrXiolTM, which is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax has competitive cooperative research and development agreements (CRADAs) for two of its prescription drug candidates, one with the National Institutes of Health (NIH) and one with the Department of Defense (DOD). Virpax is also seeking partners for two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and EpoladermTM, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit https://www.virpaxpharma.com .and follow us on Twitter, LinkedIn and YouTube. Forward-Looking Statements This press release contains certain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including those described below. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors, including the additional capital which will be necessary to complete studies and clinical trials that the Company plans to initiate and other factors listed under “Risk Factors” in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that the Company has filed with the U.S. Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. View source version on businesswire.com : https://www.businesswire.com/news/home/20241121242163/en/ CONTACT: Investor Contact: info@virpaxpharma.com KEYWORD: PENNSYLVANIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL DEVICES HEALTH PHARMACEUTICAL MEDICAL SUPPLIES SOURCE: Virpax Pharmaceuticals, Inc. Copyright Business Wire 2024. PUB: 11/21/2024 04:05 PM/DISC: 11/21/2024 04:06 PM http://www.businesswire.com/news/home/20241121242163/en

Watch: Is Jerod Mayo holding the Patriots back?In what is being called a ‘gross failure’ of security, a stowaway was able to evade multiple security checkpoints to board a flight from New York to Paris, where she was caught after disrupting the flight. A on CNN says a woman identified as Svetlana Dali completed security screening and bypassed two identity verification and boarding status stations without a boarding pass – which the Transportation Security Administration (TSA) confirms. Although TSA has not shared further details on how Dali skirted , reports say she got through without showing a boarding pass, passport – or, presumably, any other form of ID – meaning fake ID or fraudulent documents were likely not involved. The BBC’s take on the story says she “managed to dodge” document and ID checks. Dali has a U.S. green card and a Russian passport, but does not qualify for entry into Europe. She is now being held in the ZAPI waiting zone at Charles de Gaulle airport, awaiting deportation back to the States. Six major airports in Thailand are expanding facial recognition options to passengers on international flights. The will be available to international travelers at airports in Chiang Mai, Chiang Rai, Don Mueang, Hat Yai, Phuket and Suvarnabhumi. Estimates say the face biometrics system will reduce boarding time per passenger from three minutes to one. It also applies to baggage drop, enabling travelers to check bags without the need for a passport or ID document. Thailand’s airport authority says stored biometric data will be erased 48 hours after registration. The biometric passenger processing system at Thailand airports was deployed by local integrator and includes kiosks and gates . It can also authenticate airport staff. The Canadian Press that Air Canada will install facial recognition gates for boarding in Vancouver, in an effort to make the process more efficient. The opt-in program will allow passengers to walk onto a plane without showing a passport or piece of physical ID. Canada’s largest airline launched a in 2023 for digital ID in its frequent traveler Maple Leaf lounges in Toronto, Calgary and San Francisco. It plans to expand its biometrics program to boarding gates at more airports soon. New biometrics deployments in Sao Paulo, Paris, Vancouver and Thailand show airports continuing their global shift toward biometrics for check-in, security and other uses. Aeroin that Brazil’s National Civil Aviation Agency (ANAC) has approved an addendum to the concession contract for Guarulhos International Airport, opening the door for new investments in facial recognition technology to be used in passenger and and immigration control. The investment of R$450 million (roughly US$74.2 million), which aims to increase security and efficiency in passenger identification and baggage processes, will be shared between and other security measures such as x-rays and explosives detectors. A featuring representatives from Idemia and Air France delves into the programme at Paris Airport to offer AI-powered luggage identification via the ALIX tool. is expanding use cases for ALIX across the airport journey, and focusing particularly on biometric bag check and return tools. Idemia notes that a key to success in a complex bag handling system is training operators to work with AI systems, so that they are seen as helping, rather than as replacements for human labor. They also note that the airport has been keen to deploy across the facility: “the airport is not an obstacle.” | | | | | | | | |